We have demonstrated a 50-fold increase in the concentration of insulin-like growth factor-binding protein-5 (IGFBP-5) in milk after 2 days of mammary involution induced by removal of the suckling young. IGFBP-5 was identified by its immunoreactivity with an antiserum to IGFBP-5 and was shown by in situ hybridization to be synthesized by the secretory epithelial cells undergoing apoptosis. Smaller increases in IGFBP-2 and -4 messenger RNAs (mRNAs) were also evident, but neither protein could be detected on Western ligand blots of milk. Preliminary evidence failed to detect mRNAs for IG-FBP-1, -3, or -6. The large increase in IGFBP-5 concentrations in milk from involuting mammary glands was inhibited by 90% if the dams received concurrent PRL injections for 2 days, but was unaffected by GH, progesterone, corticosterone, or an antiserum to insulin-like growth factor I (IGF-I). In lactating rats allowed to continue nursing their young, 17␤-estradiol failed to affect IGFBP-5 concentrations, whereas in animals that had half the teats sealed to prevent milk removal, IGFBP-5 concentrations increased 5-to 10-fold in the sealed gland compared with those in the contralateral gland where milk removal continued. The changes in IGFBP-5 concentrations in milk were accompanied by similar changes in steady state mRNA levels of IGFBP-5 in mammary tissue. We have previously shown that PRL inhibits apoptosis and involution of the mammary gland, whereas teat sealing has the opposite effect. We, therefore, propose that IGFBP-5 serves to inhibit IGF-I-mediated cell survival, but that it is normally suppressed by PRL and milk removal. Although IGFBP-5, when bound to extracellular matrix, augments the action of IGF, we believe that in the involuting mammary gland IGFBP-5 inhibits IGF action by interacting with casein micelles, which contain calcium phosphate nanoclusters, thereby preventing IGF interaction with IGF receptors. This is analogous to the interaction of IGFBP-5 with hydroxyapatite, which serves to sequester IGFs in bone. IGFBP-5 may, in fact, play a central role in inducing apoptosis, as it is also up-regulated in involuting prostate and thyroid glands as well as in atretic ovarian follicles. (Endocrinology 138: [5101][5102][5103][5104][5105][5106][5107] 1997) 
W E HAVE previously shown that PRL and GH play interactive roles in regulating milk synthesis in the mammary gland (1) (2) (3) . Surprisingly, a large proportion of their effects can be explained not by regulation of metabolic activity of the cells, but by augmenting cell survival rates (4, 5) . To date, no mechanism by which these two hormones might play an interactive role has been suggested, as GH has been proposed to act indirectly via insulin-like growth factor I (IGF-I), whereas PRL appears to act via an IGF-independent mechanism, acting directly upon the mammary epithelial cells (6) .
During involution of the mammary gland, induced by removal of the suckling young, we identified the appearance in milk of an IGF-binding protein (IGFBP) (5) . We hypothesized that as IGF-I has been described as an important survival factor for mammary epithelial cells (7) (8) (9) and thus can inhibit involution of the mammary gland after removal of the young, the epithelial cells produce an IGFBP to inhibit IGF-mediated cell survival in order for mammary cell death to occur. As such, this IGFBP could play a key role in the programed cell death known to occur during involution of the mammary gland.
To investigate this hypothesis further, we sought to identify the precise IGFBP produced and its site of production and to characterize control of its synthesis and secretion. As cessation of milk production leads to rapid changes in the serum concentrations of PRL, 17␤-estradiol, progesterone, and IGF-I, we concentrated our initial studies on these hormones. We also included corticosterone and GH, because both have been implicated in the control of mammary involution (4, 5, 10) .
Materials and Methods Animals
Female Wistar rats, approximately 250 -300 g BW, were mated, and at parturition litters were adjusted to 10 pups. All animals were allowed free access to food (Labsure irradiated CRM diet, Labsure, Poole, UK) and water. glands were dissected out. A portion of tissue was stored in liquid N 2 for preparation of RNA, whereas a second portion was stored at Ϫ80 C for in situ hybridization studies as described below. Some animals were anesthetized with 0.3 ml sodium pentobarbitol (60 mg/ml; Sagatal, RMB Animal Health, Dagenham, UK), after which the dam received 1 U oxytocin (Intervet UK, Cambridge, UK) to induce milk ejection. Milk was obtained from the mammary gland by gentle pressure and stored at Ϫ20 C until used for the detection of IGFBPs by Western ligand blotting (11) and Western immunoblotting as described below.
Study 2: hormonal control of IGFBP synthesis and secretion in lactating rats
Lactating rats were treated on day 14 of lactation by daily administration of 17␤-estradiol (100 g in safflower oil/injection). A second group of animals had teats on one side sealed with tissue glue (Vetbond, Vet Drug Co., Falkirk, UK), and pup number was reduced to six (one per unsealed gland). After treatment for 2 days, litters were removed from these groups for 4 h to allow milk to accumulate before milking as described above.
Study 3: hormonal control of IGFBP synthesis and secretion after litter removal
Animals had litters removed on day 14 of lactation (time zero) and received one of the following treatments for 2 days, all given by sc injection: recombinant bovine GH (1 mg in 20% PVP/injection) twice daily, PRL (1 mg in 20% polyvinylpyrrolidone (PVP)/injection) twice daily, hydrocortisone (1 mg in safflower oil/injection) once daily, progesterone (5 mg in safflower oil/injection) once daily, or anti-IGF-I serum (1 ml/injection) once daily or were left untreated. All of these treatment doses were based on previous studies in which they have been shown to be effective. The anti-IGF-I serum was administered to inhibit the potential effects of the increase in serum IGF-I that occurs after litter removal. This antiserum has previously been shown to inhibit IGF-I action at the doses used in this study (12) . After treatment for 2 days, a milk sample was obtained from the upper abdominal mammary glands, as described above, and stored at Ϫ20 C. The animals were then killed by cervical dislocation, and the lower abdominal mammary glands were removed and stored in liquid N 2 for subsequent RNA isolation.
Northern blot analysis of RNA
Samples of total cellular RNA (20 g) were separated by electrophoresis in 1.2% agarose gels containing 2.2 m formaldehyde (13) and transferred to Biotrans membrane (ICN, Amsterdam, The Netherlands). These were then hybridized to a labeled antisense RNA probe for rat IGFBP-5 (a gift from Dr. S. Shimasaki, Department of Molecular Endocrinology, The Whittier Institute, La Jolla, CA). Blots were exposed to a phosphor screen, and the image was scanned in a Molecular Dynamics PhosphorImager 445SI and analyzed with ImageQuant software (Molecular Dynamics, Sunnyvale, CA. Results were standardized for the amount of 28S ribosomal RNA in each sample, as previously described (14) .
In situ hybridization studies
Frozen sections of rat mammary gland obtained from control lactating animals or after litter removal for 48 h were probed for IGFBP messenger RNA (mRNA). Sections were dehydrated in 100% ethanol twice for 5 min each time, then fixed in 2% formaldehyde in 100 mm Tris-HCl and 50 mm EDTA, pH 8.0, for 5 min. The sections were rinsed in distilled water for 5 min, and the tissue was permeabilized in 10 g/ml proteinase K, 50 mm EDTA, and 1200 mm Tris-HCl, pH 8.0, for 30 min at 37 C. After fixation in 2% formaldehyde solution, sections were rinsed in water, then in 100 mm triethanolamine, pH 8.0, for 2.5 min and acetylated for 10 min at room temperature in 100 mm triethanolamine, pH 8.0, and 0.0025% (vol/vol) acetic anhydride. The sections were rinsed briefly in 2 ϫ SSC (standard saline citrate) and dehydrated in a graded ethanol series (50%, 70%, 95%, 100%, and 100%) for 3 min each, dried under vacuum, and stored desiccated at Ϫ20 C.
Antisense and sense RNA probes were prepared by incubating 1 ng template DNA, 200 Ci [
35 S]UTP, 50 mm GTP/CTP/ATP, 20 U RNA polymerase, 20 U ribonuclease inhibitor, 5 mm dithiothreitol (DTT), 2 mm spermidine, 10 mm NaCl, 6 mm MgCl 2 , and 40 mm Tris-HCl, pH 7.5, in a final volume of 20 l at 37 C for 2 h. Deoxyribonuclease I (1 U) was then added at 37 C for 15 min, the reaction was stopped by adding 100 mm EDTA, pH 8.0, and the labeled probe was separated from unincorporated label using a Sephadex G-50 column. Sections were prehybridized overnight at 55 C in a humidified chamber in 100 l hybridization buffer consisting of 0.5 mg/ml transfer RNA, 0.5 mg/ml Torula yeast transfer RNA, 10 mm DTT, 50% formamide, 10% dextran sulfate, 0.2 mg/ml Ficoll 400, 0.2 mg/ml PVP, 0.2 mg/ml BSA, 1 mm EDTA, 300 mm NaCl, and 10 mm Tris-HCl, pH 8.0. Sections were then hybridized with 1 ϫ 10 7 cpm 35 S RNA probe in 70 l hybridization buffer under a coverslip overnight at 55 C in a humidifed chamber.
After hybridization, the coverslips were soaked off in 4 ϫ SSC and treated with 20 g/ml ribonuclease A in 500 mm NaCl, 1 mm EDTA, and 10 mm Tris-HCl, pH 8.0, for 30 min at 37 C. The sections were then washed as follows: twice in 2 ϫ SSC and 1 mm DTT for 10 min at room temperature, once in 0.5 ϫ SSC for 20 min, and once in 0.1 ϫ SSC and 1 mm DTT at 65 C for 60 min and rinsed once in 0.1 ϫ SSC and 1 mm DTT. Sections were dehydrated for 3 min each in 50% ethanol in 0.1 ϫ SSC-1 mm DTT, 70% ethanol in 0.1 ϫ SSC-1 mm DTT, 95% ethanol, and 100% ethanol. After vacuum drying for 30 min at room temperature, the sections were exposed to ␤-Max Hyperfilm (Amersham International, Little Chalfont, UK) for 3 weeks to estimate the extent of hybridization. The sections were subsequently coated in NTB-2 emulsion (IBI, Cambridge, UK) diluted 1:2 with water, exposed at 4 C, developed, counterstained, dehydrated, mounted, and examined under dark-and lightfield microscopy.
Western immunoblotting for IGFBP-5
Western blots for IGFBP-5 detection were blocked in 3% Nonidet P-40 in Tris-buffered saline (TBS) for 30 min, 1% BSA in TBS for 2 h, and 0.1% Tween-20 in TBS for 10 min, all at 4 C. Blots were then incubated overnight at 4 C in a sealed plastic bag with a 1/1000 dilution of antiserum to IGFBP-5 (a gift from Dr. D. R. Clemmons) in TBS with 1% BSA and 0.1% Tween-20. The blots were washed for 10 min using four changes of TBS-0.1% Tween and incubated at room temperature for 45 min with affinity-purified peroxidase-conjugated antiguinea pig IgG antiserum diluted in TBS, 1% BSA, and 0.1% Tween-20. The blot was washed as described above and incubated for 1 min with Enhanced Chemiluminescence reagent (Amersham International, Little Chalfont, UK), then exposed to Reflection film (DuPont, Stevenage, UK) at room temperature.
Preparation of casein micelles and whey fractions from milk
Milk samples were diluted 10-fold in 10 mm phosphate buffer, pH 7.4, and centrifuged at 100,000 ϫ g for 20 min, and the pellet (casein micelles) and supernatant (whey fraction) were separated by aspiration. Samples were then subjected to Western ligand blotting as described above to determine the presence or absence of IGFBP in each fraction.
Statistical analysis
Statistical analyses were undertaken using one-way ANOVA. Where significant differences were found, Tukey's multiple comparisons test was used to determine significant differences between individual groups. Comparisons of sealed and unsealed glands from the same animals were made using Student's paired t test.
Results

Study 1
To identify the precise IGFBP present in milk, Western ligand blots and Western immunoblots were performed using milk samples derived from lactating or involuting mammary gland. Figure 1 shows that the major IGFBP present in involuting mammary gland could be detected using an antiserum to IGFBP-5. To determine whether IGFBP-5 was being synthesized in the mammary gland, as opposed to being transported from blood into milk, Northern analysis was performed. Figure 2 clearly demonstrated the dramatic increase in expression of IGFBP-5 mRNA 48 h after involution of the mammary gland commenced. There was also a modest increase in expression of IGFBP-4, although there was no evidence of its presence in milk. The site of synthesis of IGFBP-5 was further localized to the mammary secretory epithelial cells by in situ hybridization (Fig. 3 ). An increase in synthesis of IGFBP-2 and -4 from epithelial cells was also evident during involution (Table 1 ). There was, however, no evidence of IGFBP-2 or -4 in milk. Preliminary in situ hybridization studies and Northern blotting failed to detect mRNAs for IGFBP-1, -3, or -6 in either lactating or involuting mammary gland (data not shown).
Study 2
Hormonal control of IGFBP-5 synthesis and secretion during lactation. The concentration of IGFBP-5 in milk samples derived from lactating animals was determined by Western ligand blotting, and the results are shown in Fig. 4 . Levels of IGFBP-5 were extremely low in milk derived from lactating mammary gland and were unaffected by administration of 17␤-estradiol to the lactating dam (to mimic the increase that occurs when estrus resumes after removal of the suckling litter). 17␤-Estradiol also failed to influence IGFBP-5 mRNA steady state levels. By contrast, in lactating animals that had half the mammary glands sealed to allow milk accumulation to occur in the presence of an unchanged hormonal environment, there was a 5-fold increase in IGFBP-5 concentrations in the sealed, but not the unsealed, glands. IGFBP-5 mRNA also increased in sealed mammary glands compared with that in their unsealed counterparts (Fig. 4) .
Study 3
Hormonal control of IGFBP-5 synthesis and secretion after litter removal. Removal of the suckling young increased the concentration of IGFBP-5 in milk even more dramatically than teat sealing, resulting in a 40-to 50-fold increase (Fig. 5) . Concurrent PRL injections markedly reduced this increase, such that values were only 5-fold higher than those in lactating animals. By contrast, treatment with an antiserum to IGF-I (to neutralize the increase in serum IGF-I that occurs after removal of the litter) or with GH, progesterone, or corticosterone failed to prevent the increase in IGFBP-5 that occurred after litter removal.
Steady state messenger RNA levels of IGFBP-5 in mammary tissue revealed an equally dramatic increase after litter removal, and again, this was markedly suppressed by PRL (Fig. 5) . Consistent with their lack of effect on IGFBP-5 concentrations in milk, treatment with GH, progesterone, corticosterone, or an antiserum to IGF-I did not significantly influence steady state levels of IGFBP-5 mRNA.
Finally, centrifugation of milk samples to produce a casein micelle fraction and a supernatant or whey fraction demonstrated that the majority of IGFBP-5 was present in the casein micelle fraction (results not shown).
Discussion
We have examined the production of IGFBPs within mammary tissue and their secretion into milk. Steady state levels of mRNA were detectable for IGFBP-2, -4, and -5, the latter two being detected principally in the involuting mammary gland. These results are similar to those reported by Donovan et al. (15) , who showed IGFBP-2 and -4 mRNA, but no evi- dence of IGFBP-1 or -3 mRNA, in lactating mammary gland. Their study did not include IGFBP-5, nor did it investigate involution, which is where the principal thrust of our study was directed. Milk derived from lactating animals contained very low levels of IGFBPs with a pattern characteristic of serum in heavily overexposed autoradiographs (data not shown), which was also consistent with previous findings (15) . However, there was a huge increase in one IGFBP during involution of the mammary gland. We identified this IGFBP present in milk derived from the involuting mammary gland as IGFBP-5 based on its apparent mol wt and its reactivity with an antibody to IGFBP-5. In addition, we have shown that it is synthesized within the secretory epithelial cells, which are known to be undergoing apoptosis or programed cell death at this time. Several recent transgenic models have demonstrated that overexpression of IGF-I within the mammary gland can retard mammary involution after removal of the suckling young (8, 9) . We thus hypothesize that one of the early events associated with involution is the secretion of IGFBP-5, which serves to inhibit IGF-Imediated cell survival. Consistent with this, IGFBP-5 synthesis increased within 24 h of litter removal, long before major structural changes or cell death had occurred. Several other observations are consistent with this hypothesis; for example, PRL, which suppressed IGFBP-5 expression, has also been demonstrated to inhibit apoptosis (5, 16), whereas teat sealing, which increases IGFBP-5, is associated with increased levels of apoptosis (17) . We also tested the effects of corticosterone because it has been proposed to inhibit involution of the mammary gland (10), but we found no effects on IGFBP-5 concentrations in milk. However, a more recent publication has proposed that glucocorticoids only delay the later, second phase of involution occurring 3-4 days after litter removal (18) , and this is consistent with our belief that IGFBP-5 is involved in the initial stages of apoptosis. Progesterone, 17␤-estradiol, systemic IGF-I, and GH were also unable to influence IGFBP-5 concentrations in milk. This was perhaps surprising with respect to IGF-I, as it has been shown to increase IGFBP-5 release from bone cells in vitro (19, 20) , and we have no obvious explanation for this lack of effect in vivo.
The inability of GH to regulate IGFBP-5 was also unexpected, as we have shown that GH can inhibit apoptosis in the rat mammary gland (5) . We have also demonstrated that GH and PRL play interactive roles in maintaining mammary gland function and cell survival, although we have previously been unable to offer any mechanistic explanation for this. We would now propose that GH plays its major role by stimulating an increase in serum IGF-I concentrations and perhaps locally produced IGF-I from the mammary stroma, but that this is less potent in maintaining mammary epithelial cell survival unless PRL is present to suppress IGFBP-5 synthesis. In support of this hypothesis, Kleinberg and co-workers (21) have shown that IGF-I is produced by the mammary stroma and that GH stimulates steady state levels of IGF-I mRNA produced by the mammary stroma.
The proposal that IGFBP-5 is important in regulating apoptosis has also been made after the use of a lateral crossscreening strategy that identified IGFBP-5 as a gene product that was up-regulated dramatically in both involuting mammary gland and prostate (22) . Indeed, IGFBP-5 expression is also increased in the involuting thyroid (23) and in ovarian follicles undergoing atresia (24) .
Although our studies reveal an excellent correlation between IGFBP-5 expression and apoptosis in the mammary gland, our immediate goal is to explore a causal relationship between the two. If our hypothesis is correct, we have to propose that IGFBP-5 produces an inhibitory, rather than augmentory, effect on IGF action. A number of studies have provided support for such an inhibitory effect of IGFBP-5 on the actions of IGF-I (25) (26) (27) (28) .
In our study we have also demonstrated an interaction of IGFBP-5 with the micelle fraction of milk. IGFBP-5 is protected from degradation by interaction with the extracellular matrix (29) , although this also leads to a reduction in the affinity of IGFBP-5 for IGF-I and is thus proposed to be part of a transport system for IGF-I delivery to cells, augmenting, rather than inhibiting, the actions of IGF-I. We are, however, intrigued by the possibility that IGFBP-5 may be interacting with the casein micelles present in milk. IGFBP-5 binds with high affinity to hydroxyapatite (a crystalline form of calcium phosphate) in bone (30) , and casein micelles also possess calcium phosphate nanoclusters (31) . In addition, IGFBP-5 has been shown to be phosphorylated (32) , and it contains a region that is a consensus sequence for the true mammary casein kinases.
Proteolysis of IGFBP-5 was evident in milk, although the majority of IGFBP-5 was intact. This is surprising in the involuting mammary gland, where a number of proteolytic enzymes are active. However, IGFBP-5 has recently been shown to interact with plasminogen-activating inhibitor-I, and this may serve to protect it from proteolysis in an analogous fashion to the effect of extracellular matrix (33) . Such an interaction of IGFBP-5 and plasminogen-activator inhibitor-I in the mammary gland is worthy of investigation. We also cannot rule out possible interactions of IGFBP-5 with the mammary cell surface, as has been proposed for endothelial cells (34) or the possibility that this involves interaction with an IGFBP-5 "receptor" (35) .
Finally, the demonstration that PRL is capable of repressing expression of IGFBP-5 mRNA in the mammary gland provides an interesting comparative model for the study of sion of AP-1 or AP-2 by PRL provides a mechanistic explanation for this phenomenon remains to be seen. The IGFBP-5 promoter also contains a CACCC box capable of binding the progesterone receptor (40) . However, the inability of progesterone to influence IGFBP-5 mRNA expression in the mammary gland in our study is readily explained by the loss of progesterone receptor expression, and thereby progesterone responsiveness, that occurs in the mammary gland during lactation (41) .
In conclusion, we have demonstrated for the first time a dramatic increase in the concentration of IGFBP-5 mRNA in the secretory epithelial cells of the involuting mammary gland and its secretion into milk. PRL, which is a major inhibitor of apoptosis, also inhibited IGFBP-5 synthesis. In addition, teat sealing, which leads to the accumulation of milk in the absence of changes in circulating hormones, led to an increase in IGFBP-5 synthesis and secretion. This suggests that locally produced, as yet unidentified, factors also play a role in regulating IGFBP-5 expression. We are currently investigating the potential role of IGFBP-5 in the regulation of apoptosis using in vitro mammary culture systems and a transgenic animal approach involving expression of IGFBP-5 on a mammary-specific promoter.
